RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
34.47
0.00 (-0.01%)
At close: Dec 5, 2025, 4:00 PM EST
33.82
-0.65 (-1.87%)
After-hours: Dec 5, 2025, 6:43 PM EST
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
955.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RAPT News
- 20 days ago - RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices - Seeking Alpha
- 4 weeks ago - RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies - GlobeNewsWire
- 6 weeks ago - RAPT Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - RAPT Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript - Seeking Alpha
- 6 weeks ago - CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why - Invezz